BioInsights - Driving the viral vector expressway: speeding through AAV manufacturing

Driving the viral vector expressway: speeding through AAV manufacturing

Cell & Gene Therapy Insights 2022; 8(10), 1371;

DOI: 10.18609/cgti.2022.198

Published: 17 November 2022
FastFacts
Andi Ushijima, Henry George


Watch this FastFacts to discover:

  •      How the VirusExpress® 293 AAV Production Platform can help speed your gene therapy to patients
  •      How high-through put screening has enhanced efficiency of the platform
  •      How improvements to transfection and cell culture media impact performance
  •      How our platform performs with GFP model virus in serotypes AAV2, AAV5, AAV6, and a customer’s GOI and AAV9.

Andi Ushijima is a Scientist in the Viral Vector Innovation and Technology group at MilliporeSigma. She has a variety of upstream bioprocessing experience working on bioreactor development and scale up of monoclonal antibodies, virus-like particles, and viral vectors. She received her BSc in Bioengineering at UCSD.

Henry has worked since 1981 in both the biotechnology and pharmaceutical sectors, developing protein expression systems in bacterial, insect and mammalian hosts. He joined MilliporeSigma in 2001 as an R&D manager, and currently leads the Viral Vector Producer Cell Lines R&D group.








We hope you enjoyed this FastFacts video. You can also view the poster summary here.



For more information on the VirusExpress® Platform, click here



Authorship & Conflict of Interest

Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Acknowledgements: None

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest.

Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article. 


Article & copyright information

Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Attribution: Copyright © 2022 Millipore Sigma. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.

Article source: From a FastFacts video recorded on: Oct 19 2022; Publication date: Nov 17 2022.